Stockscreener 앱 받기
72.81
0.15%
0.11
시간 외 거래:
72.81
전일 마감가:
$72.70
열려 있는:
$72.88
하루 거래량:
413.97K
Relative Volume:
0.44
시가총액:
$3.20B
수익:
$535.08M
순이익/손실:
$-48.27M
주가수익비율:
-64.23
EPS:
-1.1335
순현금흐름:
$-31.54M
1주 성능:
+3.11%
1개월 성능:
+24.12%
6개월 성능:
-2.93%
1년 성능:
+27.18%
1일 변동 폭
$71.77
$73.08
1주일 범위
$69.67
$73.51
52주 변동 폭
$48.20
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
명칭
Tarsus Pharmaceuticals Inc
전화
(949) 409-9820
주소
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
72.81 | 3.14B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-11-20 | 개시 | Mizuho | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-27 | 재개 | H.C. Wainwright | Buy |
| 2023-11-20 | 개시 | Goldman | Neutral |
| 2023-07-18 | 개시 | William Blair | Outperform |
| 2023-05-18 | 개시 | Guggenheim | Buy |
| 2022-08-01 | 개시 | Barclays | Overweight |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-23 | 개시 | Oppenheimer | Outperform |
| 2020-11-10 | 개시 | BofA Securities | Buy |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Ladenburg Thalmann | Buy |
| 2020-11-10 | 개시 | Raymond James | Strong Buy |
모두보기
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus (TARS) Technicals: Finishes 1.69% Up at $72.70 in the Latest Session; Next Test: Support at $69.06 and Resistance at $76.34 Frame the Range in Latest TradingVWAP Bounce - vinanet.vn
Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares - Stock Titan
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Stocktwits
Midday Stock Roundup: Eledon Falls 3.5% - Orange County Business Journal
TimesSquare Capital Management LLC Takes $23.25 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales GuidanceAnd What's Next - Sahm
Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? - Sahm
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q2 2026 Tarsus Pharmaceuticals, Inc. Earnings Call Transcript - GuruFocus
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak - Yahoo Finance
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus - Stock Titan
Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
How (TARS) Movements Inform Risk Allocation Models - Stock Traders Daily
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Tarsus Pharmaceuticals (TARS) Holds Above $65 Support After Modest Pullback to $68.68Gap Up Stocks - vinanet.vn
TARS Maintained by Oppenheimer -- Price Target Raised to $100 - GuruFocus
Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating - marketscreener.com
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100 - Moomoo
Tarsus Pharmaceuticals (TARS) Surges 4.6% to $67.76, Pressing Against ResistanceChandelier Stop - vinanet.vn
Tarsus Pharmaceuticals Signs Agreement to Acquire Alkeus Pharmaceuticals - Global Legal Chronicle
The Manufacturers Life Insurance Company Cuts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals, Inc. $TARS Shares Acquired by Bank of America Corp DE - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus - Sahm
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $104 - Moomoo
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results - MarketBeat
Deal Watch: Tarsus Seeks Another Ophthalmology Buy With Alkeus Takeout Bid - insights.citeline.com
Tarsus Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88 - Moomoo
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $104 - Moomoo
Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating - marketscreener.com
Tarsus joins Stargardt race to market with $800m Alkeus takeover - Yahoo Finance
Tarsus Pharmaceuticals acquires iRenix for $75 million upfront By Investing.com - Investing.com Nigeria
Tarsus to acquire Alkeus for $450M upfront plus milestones By Investing.com - Investing.com South Africa
Tarsus to Acquire Alkeus in $450 Million Deal, Reports Strong Quarter and Half - VisionMonday.com
Latham & Watkins Advises Alkeus Pharmaceuticals on Acquisition by Tarsus Pharmaceuticals - Latham & Watkins LLP
Tarsus Bets Up To $800M On Alkeus In Retina Therapy Push - Law360
Tarsus Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $93.57, Implies 53% Upside - TradingView
Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highli - GuruFocus
Tarsus to purchase Alkeus Pharmaceuticals - glance.eyesoneyecare.com
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M - BioPharma Dive
Tarsus Pharmaceuticals, Inc. entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc. for approximately $800 million. - marketscreener.com
Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ... - Yahoo Finance
Tarsus Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TARS) 2026-08-06 - Seeking Alpha
Tarsus Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Tarsus Pharmaceuticals Raises 2026 XDEMVY Net Pdt Sales Guidance to $685M-$705M >TARS - Moomoo
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Tarsus Pharmaceuticals (TARS) Positioned for Growth After Q2 - GuruFocus
Tarsus Pharmaceuticals, Inc. - Reuters
Tarsus Pharmaceuticals posts Q2 XDEMVY sales of $173.9 million By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals Inc (TARS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tarsus Pharmaceuticals Inc 주식 (TARS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Azamian Bobak R. | President/CEO and Board Chair |
Jun 17 '26 |
Sale |
61.55 |
10,000 |
615,488 |
847,991 |
| Farrow Jeffrey S | See Remarks |
Jun 16 '26 |
Sale |
60.95 |
14,396 |
877,436 |
56,801 |
| Goodrich Katherine | Director |
Jun 15 '26 |
Sale |
62.08 |
2,954 |
183,384 |
2,233 |
| LINK WILLIAM J PHD | Director |
Jun 15 '26 |
Sale |
62.12 |
12,500 |
776,495 |
106,786 |
0.00%
3.22%
자본화:
|
볼륨(24시간):